Whenever a person has severe brain trauma, inflammation occurs which pushes the brain against the brain cage. This pressure causes an electrochemical to be released in the brain which results in the formation of fluids in the heart and lungs (cardiac arrhythmia and pulmonary edema). The fluids can fill the lungs within hours resulting in death. Currently the drug Mannitol is prescribed for administration two to three times daily to help to reduce the swelling. There have been no improvements in this drug category for over forty years and there are still high incidences of mortality from cardiac arrhythmia and pulmonary edema complications due to traumatic brain injury. Clearly, Mannitol does not reduce complications of cardiac arrhythmia and pulmonary edema.

EndogenX is bringing to market a new formulation of Mannitol that will not only reduce the brain edema but will significantly reduce the cardiac arrhythmias and pulmonary edema complications of brain edema. The ability to reduce the mortality rate of victims of traumatic brain injury - currently in excess of 2 million cases annually - presents a great opportunity. Additionally, this new drug would be a tremendous asset to the more than 125,000 brain neurosurgery cases performed each year.

	Research		Development		Market
ENDG2010 CNS Inflammation, Endothelin based formulation
ENDG2020 CNS Inflammation, Mannitol modification